Home > Oncology > ASCO 2019 > Genitourinary Cancer - Prostate Cancer > Enzalutamide offers survival advantage over other NSAAs in mHSPC

Enzalutamide offers survival advantage over other NSAAs in mHSPC

Presented By
Dr Christopher Sweeney, Dana-Farber Cancer Institute, USA
Conference
ASCO 2019
Trial
ENZAMET, TITAN
  Medical writer: Dave Levitan Enzalutamide and testosterone suppression significantly prolonged overall survival compared with other nonsteroidal anti-androgens (NSAAs) and testosterone suppression in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to the interim analysis from the phase III ENZAMET trial (Abstract LBA2). Enzalutamide is a potent direct inhibitor of the androgen receptor (AR), with established benefit in castration-resistant prostate cancer. ENZAMET randomly assigned 1,125 men with mHSPC to either testosterone suppression and other NSAAs, including bicalutamide, nilutamide, or flutamide (562 patients), or testosterone suppression and enzalutamide (563 patients). On May 31, results of the TITAN study (Abstract 5006) were presented, showing that the addition of another AR inhibitor, apalutamide, can significantly improve survival when added to androgen-deprivation therapy; this was regardless of pri...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on